<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Teriparatide (including biosimilars available in Canada): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Teriparatide (including biosimilars available in Canada): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Teriparatide (including biosimilars available in Canada): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11081" href="/d/html/11081.html" rel="external">see "Teriparatide (including biosimilars available in Canada): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F225837"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Forteo</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868369"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Forteo;</li>
<li>TEVA-Teriparatide</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F225853"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Parathyroid Hormone Analog</li></ul></div>
<div class="block doa drugH1Div" id="F225839"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Assess serum calcium prior to initiation; avoid use in patients with preexisting hypercalcemia or hypercalcemic disorder. Correct vitamin D deficiency (eg, to a 25-hydroxyvitamin D level ≥20 ng/mL [≥50 nmol/L]) prior to initiating therapy and ensure adequate calcium and vitamin D intake during therapy; however, use caution to avoid hypercalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-15872215','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-15872215','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b39ecfae-fc98-4a25-907f-5cc1de30de91">Osteoporosis, glucocorticoid induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, glucocorticoid induced (alternative agent): Note:</b> Alternative agent if bisphosphonate therapy is not appropriate. Avoid use in women who are pregnant, who plan on becoming pregnant, or who are not using effective birth control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b>: 20 mcg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42d9f687-8a9c-4d6e-86a3-00829eb78170">Osteoporosis, fracture risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, fracture risk reduction (males and postmenopausal females): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as initial therapy in patients with very high fracture risk, including those with a T-score less than –3, a T-score less than –2.5 with fragility fracture history, or severe or multiple prior vertebral fractures. May also be used as an alternative agent in patients with high fracture risk in whom first-line therapies are ineffective or cannot be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27643923','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27643923','lexi-content-ref-30907953'])">Ref</a></span>). Prior to use, evaluate and treat any potential causes of secondary osteoporosis (eg, severe vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 20 mcg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Duration of therapy:</b> Duration of teriparatide therapy should generally not exceed 2 years due to limited data with use beyond this; fracture reduction efficacy has been demonstrated over a period of 18 to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29329484','lexi-content-ref-11346808','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29329484','lexi-content-ref-11346808','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation/interruption of therapy:</b> Following a course of teriparatide, switch to antiresorptive therapy (eg, with a bisphosphonate or denosumab) to maintain bone density gains (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990677"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24361089','lexi-content-ref-27895472','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24361089','lexi-content-ref-27895472','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use only in patients at very high risk for fracture and in conjunction with guidance from patient's nephrology team, as osteoporosis can be difficult to distinguish from chronic kidney disease mineral and bone disorder (CKD-MDB); many patients with CKD-MBD will already have elevated parathyroid hormone levels, and teriparatide safety and efficacy data are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24726630','lexi-content-ref-17013567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24726630','lexi-content-ref-17013567'])">Ref</a></span>). If treatment is necessary, no dosage adjustment is likely to be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (large molecular weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): Use should generally be avoided. If treatment is necessary, dose as in eGFR &lt;30 mL/minute/1.73m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20588059','lexi-content-ref-25815175','lexi-content-ref-25843705','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20588059','lexi-content-ref-25815175','lexi-content-ref-25843705','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large molecular weight): Use should generally be avoided. If treatment is necessary, dose as in eGFR &lt;30 mL/minute/1.73m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372586','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372586','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987945"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F3062230"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F225806"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (females: 11%; males: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (9% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (3%), syncope (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (5%), gastritis (7%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2% to 3%; neutralizing antibodies: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (4%), asthenia (9%), depression (4%), dizziness (8%), headache (8%), insomnia (5%), vertigo (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10%), lower limb cramp (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (4% to 6%; including acute dyspnea), pharyngitis (6%), pneumonia (3% to 6%), rhinitis (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Orthostatic hypotension (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous calcification (including calciphylaxis and exacerbation of cutaneous calcification)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Osteosarcoma</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, hypersensitivity reaction (including anaphylaxis and angioedema), mouth edema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including bruising at injection site, pain at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm</p></div>
<div class="block coi drugH1Div" id="F225821"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema) to teriparatide or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Preexisting hypercalcemia; severe renal impairment; metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and Paget disease of the bone); unexplained elevations of alkaline phosphatase; prior external beam or implant radiation therapy involving the skeleton; bone metastases or history of skeletal malignancies; pregnancy; breastfeeding; pediatric patients or young adults with open epiphysis.</p></div>
<div class="block war drugH1Div" id="F225804"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous calcification: Serious worsening of previous stable cutaneous calcification or calciphylaxis has been reported; discontinue use if occurs. Patients with underlying autoimmune disease, kidney failure, or concomitantly taking warfarin or systemic corticosteroids are at increased risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension: May cause orthostatic hypotension. Transient orthostatic hypotension usually occurs within 4 hours of dosing and within the first several doses; usually resolved without treatment within a few minutes to a few hours.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteosarcoma: Generic product: There have been postmarketing reports of osteosarcoma; however, an increased risk has not been observed in observational studies. Avoid use in patients at an increased baseline risk of osteosarcoma (eg, open epiphyses, metabolic bone diseases other than osteoporosis [Paget disease], bone metastases, history of skeletal malignancies, previous external beam or implant skeletal radiation, hereditary disorders predisposing to osteosarcoma).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Use with caution in patients with hypercalcemia (not studied); may increase or exacerbate hypercalcemia. Avoid use in patients with known or history of hypercalcemia disorder (eg, primary hyperparathyroidism).</p>
<p style="text-indent:-2em;margin-left:4em;">• Urolithiasis: Use with caution in patients with active or recent urolithiasis because of risk of exacerbation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple-dose injection pens: According to the Centers for Disease Control and Prevention, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p></div>
<div class="block foc drugH1Div" id="F225815"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Forteo: 600 mcg/2.4 mL (2.4 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mcg/2.4 mL (2.4 mL); 620 mcg/2.48 mL (2.48 mL)</p></div>
<div class="block geq drugH1Div" id="F225800"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F225824"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Forteo Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mcg/2.4 mL (per mL): $2,144.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Teriparatide (Recombinant) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mcg/2.4 mL (per mL): $1,978.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">620MCG/2.48ML (per mL): $1,197.58</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868370"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Forteo: 750 mcg/3 mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mcg/2.4 mL (2.4 mL)</p></div>
<div class="block adm drugH1Div" id="F225818"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Initial administration should occur under circumstances in which the patient may sit or lie down, in the event of orthostasis.</p>
<p style="text-indent:-2em;margin-left:2em;">Inject into the thigh or abdominal wall. Administer without regard to meals or time of day. May administer dose immediately following removal from the refrigerator. Each teriparatide delivery device can be used for up to 28 days after the first injection. <b>Note:</b> The 3 mL prefilled pen [Canadian product] must be primed prior to each dose.</p></div>
<div class="block meg drugH1Div" id="F7874998"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:0em;margin-left:2em;">Bonsity: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F211939s004lbl.pdf%23page%3D23&amp;token=eiy8UXRHSnsm5%2F5pCmVuvp%2Bb3bhjYtygza4MSiAx%2FApL19wGTY5zoBTA6nUW24Wpq22ibQnBfrTiffr9tQ7IEqMdmFFvB9NaZrKlXVe2xpvgoX2wpaj%2Bur0Riohk9Qs2&amp;TOPIC_ID=10178" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211939s004lbl.pdf#page=23</a></p></div>
<div class="block use drugH1Div" id="F225817"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis:</b> Treatment of osteoporosis in postmenopausal females who are at high risk for fracture (defined as history of osteoporotic fracture or multiple risk factors for fracture); treatment to increase bone mass in males with primary or hypogonadal osteoporosis who are high risk for fracture; treatment of males and females with glucocorticoid-induced osteoporosis associated with chronic systemic glucocorticoids with a prednisone dosage of ≥5 mg/day (or equivalent) at a high risk for fracture. May also be used in patients who have failed or are intolerant to other available osteoporosis therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Cumulative lifetime duration of teriparatide beyond 2 years should only be considered if a patient remains at or has returned to having a high risk of fracture.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In Canada, Osnuvo is approved as a biosimilar to Forteo.</p></div>
<div class="block mst drugH1Div" id="F15255018"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Teriparatide may be confused with tirzepatide.</p>
<p style="text-indent:-2em;margin-left:4em;">Forteo may be confused with Forfivo XL</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300117"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223234"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F225825"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in animal reproduction studies; consider discontinuing treatment once pregnancy is recognized.</p></div>
<div class="block brc drugH1Div" id="F225826"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if teriparatide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends avoiding use in patients who are breastfeeding.</p></div>
<div class="block dic drugH1Div" id="F21303675"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]). Some clinicians have suggested limiting calcium to ≤1,000 mg/day in patients taking teriparatide (Licata 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D: 800 to 1,000 units/day (age ≥50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 units/day (age ≤70 years) <b>or</b> 800 units/day (age ≥71 years) (IOM 2011).</p></div>
<div class="block mop drugH1Div" id="F225812"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Orthostatic hypotension; serum calcium (draw at least 16 hours after teriparatide dose); urinary calcium (patients with suspected active urolithiasis or preexisting hypercalciuria).</p>
<p style="text-indent:-2em;margin-left:2em;">Bone mineral density (BMD) should be evaluated at baseline and ~1 to 2 years following initiation of therapy) (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); may consider monitoring biochemical markers of bone turnover (eg, serum P1NP) at baseline, 3 months, and 6 months to assess treatment response (ES [Eastell 2019]; Miller 2016).</p></div>
<div class="block pha drugH1Div" id="F225803"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Teriparatide is a recombinant formulation of endogenous parathyroid hormone (PTH), containing a 34-amino-acid sequence which is identical to the N-terminal portion of this hormone. The pharmacologic activity of teriparatide, which is similar to the physiologic activity of PTH, includes stimulating osteoblast function, increasing gastrointestinal calcium absorption, and increasing renal tubular reabsorption of calcium. Treatment with teriparatide results in increased bone mineral density, bone mass, and strength. In postmenopausal females, teriparatide has been shown to decrease osteoporosis-related fractures.</p></div>
<div class="block phk drugH1Div" id="F225820"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~0.12 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (nonspecific proteolysis).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: 5 minutes; SubQ: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51160034"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with severe renal impairment (CrCl less than 30 mL/min), the AUC and half-life increased 73% and 77%, respectively. Maximum serum concentration was not increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Systemic exposure is approximately 20% to 30% lower in males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F225827"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Forteo | Osteofortil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Osteoteri | Sondelbay | Terrosa</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Livogiva | Sondelbay | Teriparatid mepha</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Formosseo | Forteo | Osteotide</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay | Terrosa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Livogiva | Movymia</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Duratil | Forsteo | Livogiva | Sondelbay</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Livogiva | Sondelbay | Teriparatide biogaran</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Teriparatide Teva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Forteo</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Movymia | Teriparatid Teva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Livogiva | Movymia | Sondelbay | Tetridar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Forteo | Gemfrac | Terifrac | Tricium pth tp 3</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Livogiva | Oseffyl | Patride | Sondelbay | Teriparatide Teva | Terrosa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Forteo | Osteotide</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Forteo</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Forteo | Forteo colter</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Qutavina | Sondelbay | Teriparatide Teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay | Teriparatida ratiopharm</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Sondelbay | Teriparatide Teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Forsteo | Movymia | Terrosa</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Forteo | Mega pth</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Forsteo</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Forteo</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Forteo | Sondelbay</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12364430">
<a name="12364430"></a>Body JJ, Gaich GA, Scheele WH, et al. A Randomized Double-blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] With Alendronate in Postmenopausal Women With Osteoporosis. <i>J Clin Endocrinol Metab</i>. 2002;87(10):4528-4535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/12364430/pubmed" id="12364430" target="_blank">12364430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28585373">
<a name="28585373"></a>Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Arthritis Rheumatol</i>. 2017;69(8):1521-1537. doi:10.1002/art.40137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/28585373/pubmed" id="28585373" target="_blank">28585373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27643923">
<a name="27643923"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/27643923/pubmed" id="27643923" target="_blank">27643923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20588059">
<a name="20588059"></a>Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study. <i>Kidney Blood Press Res</i>. 2010;33(3):221-226. doi:10.1159/000316708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/20588059/pubmed" id="20588059" target="_blank">20588059</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference">
                  Forteo (teriparatide) [prescribing information]. Indianapolis, IN: Lilly USA LLC; September 2021.</div>
</li>
<li>
<div class="reference">
                  Forteo (teriparatide) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29329484">
<a name="29329484"></a>Geusens P, Marin F, Kendler DL, et al. Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO Trial. <i>J Bone Miner Res</i>. 2018;33(5):783-794. doi:10.1002/jbmr.3384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/29329484/pubmed" id="29329484" target="_blank">29329484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25815175">
<a name="25815175"></a>Giamalis P, Economidou D, Dimitriadis C, Memmos D, Papagianni A, Efstratiadis G. Treatment of adynamic bone disease in a haemodialysis patient with teriparatide. <i>Clin Kidney J</i>. 2015;8(2):188-190. doi:10.1093/ckj/sfv005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/25815175/pubmed" id="25815175" target="_blank">25815175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24361089">
<a name="24361089"></a>Imai H, Watanabe M, Fujita T, Watanabe H, Harada K, Moritoyo T; ANTCliPh (Academic Network for Trials in Clinical Pharmacology ) Trial 04 Study Group. Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. <i>Int J Clin Pharmacol Ther</i>. 2014;52(2):166-174. doi:10.5414/CP202001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/24361089/pubmed" id="24361089" target="_blank">24361089</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine). <i>Dietary Reference Intakes for Calcium and Vitamin D.</i> Washington, DC: The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15872215">
<a name="15872215"></a>Licata AA. Osteoporosis, teriparatide, and dosing of calcium and vitamin D. <i>N Engl J Med</i>. 2005;352(18):1930-1931. doi:10.1056/NEJM200505053521822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/15872215/pubmed" id="15872215" target="_blank">15872215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24726630">
<a name="24726630"></a>Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. <i>Am J Kidney Dis</i>. 2014;64(2):290-304. doi:10.1053/j.ajkd.2013.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/24726630/pubmed" id="24726630" target="_blank">24726630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27533157">
<a name="27533157"></a>Miller PD, Hattersley G, Riis BJ, et al; ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. <i>JAMA</i>. 2016;316(7):722-733. doi:10.1001/jama.2016.11136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/27533157/pubmed" id="27533157" target="_blank">27533157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17013567">
<a name="17013567"></a>Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. <i>Osteoporos Int</i>. 2007;18(1):59-68. doi:10.1007/s00198-006-0189-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/17013567/pubmed" id="17013567" target="_blank">17013567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11346808">
<a name="11346808"></a>Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis. <i>N Engl J Med.</i> 2001;344(19):1434-1441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/11346808/pubmed" id="11346808" target="_blank">11346808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27895472">
<a name="27895472"></a>Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. <i>Clin Interv Aging</i>. 2016;11:1653-1659. doi:10.2147/CIA.S120175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/27895472/pubmed" id="27895472" target="_blank">27895472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Osnuvo (teriparatide) [product monograph]. Blainville, Quebec, Canada: AVIR Pharma Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25843705">
<a name="25843705"></a>Palcu P, Dion N, Ste-Marie LG, et al. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. <i>Am J Kidney Dis</i>. 2015;65(6):933-936. doi:10.1053/j.ajkd.2015.01.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/25843705/pubmed" id="25843705" target="_blank">25843705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31372586">
<a name="31372586"></a>Peugh J, Khalil A, Chan MR, Hansen KE. Teriparatide treatment for hypercalcemia associated with adynamic bone disease. <i>JBMR Plus</i>. 2019;3(7):e10176. doi:10.1002/jbm4.10176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/31372586/pubmed" id="31372586" target="_blank">31372586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11859030">
<a name="11859030"></a>Reeve J. Recombinant Human Parathyroid Hormone. <i>BMJ</i>. 2002;324(7335):435-436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/11859030/pubmed" id="11859030" target="_blank">11859030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18003959">
<a name="18003959"></a>Saag KG, Shane E, Boonen S, et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. <i>N Engl J Med</i>. 2007;357(20):2028-2039.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teriparatide-including-biosimilars-available-in-canada-drug-information/abstract-text/18003959/pubmed" id="18003959" target="_blank">18003959</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Teriparatide [prescribing information]. Morristown, NJ: Alvogen Inc; November 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10178 Version 191.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
